Evading tumor immune surveillance is now recognized as a hallmark of tumor development, leading to the investigation of therapeutic targets such as programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)8. This evidence concerns the gene CD274 and neoplasm.